Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
JW (Cayman) Therapeutics Co. Ltd. (HK:2126)
HKEX:2126
JW (Cayman) Therapeutics Co. Ltd. (2126) Stock Price & Analysis
0 Followers
2126 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$1.58 - HK$3.49
Previous CloseHK$1.96
Volume31.59K
Average Volume (3M)478.52K
Market Cap
HK$813.35M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 27, 2024EPS Estimate
-HK$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.09
Shares Outstanding414,358,958
10 Day Avg. Volume4,953,000
30 Day Avg. Volume478,521
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
JW (Cayman) Therapeutics Co. Ltd. News
PremiumCompany Announcements
JW Therapeutics Shareholders Approve Key Resolutions
PremiumCompany Announcements
JW Therapeutics’ Breakthrough in SLE TreatmentOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.54% Mutual Funds
0.03% Other Institutional Investors
99.43% Public Companies and
Individual Investors
2126 FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.58 and its highest was HK$3.49 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
Currently, no data Available
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Aug 27, 2024 which is in 57 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Mar 20, 2024. The company reported -HK$1.01 earnings per share for the quarter, missing the consensus estimate of -HK$0.87 by -HK$0.14.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate is -HK$0.69.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 414,975,860 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$1.01 in its last earnings report, missing expectations of -HK$0.87. Following the earnings report the stock price went down -0.98%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in HK:2126
---
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.83%
12-Months-Change
Fundamentals
Return on Equity
-37.75%
Trailing 12-Months
Asset Growth
-24.60%
Trailing 12-Months
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
---
2126 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
EC Healthcare
―
Netjoy Holdings Limited
―
MicroPort NeuroTech Limited
―
CN Logistics International Holdings Limited
―
Best Analysts Covering 2126
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-19.00%
reiterated a buy rating 10 months ago
Copying Ziyi Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -19.00% per trade.
---